Effectiveness of radioiodine therapy with 131I-metaiodobenzylguanidine (131I-MIBG) for the treatment of neuroblastoma
DOI:
https://doi.org/10.33448/rsd-v12i4.40685Keywords:
Radiation treatment; Survival; I-meta-iodobenzylguanidine; Neuroblastoma.Abstract
Objective: To assess whether radioiodine therapy with 131I-metaiodobenzylguanidine (131I-mIBG) increases the survival of patients diagnosed with neuroblastoma, avid-mIBG, refractory to treatment or at high risk for recurrence, regardless of disease stage. Methods: Systematic review of the literature. Medline databases (PUBMED), EMBASE and Cochrane Library were consulted, including studies available in full text, published in English, Spanish or Portuguese. Outcomes of interest were overall and progression-free survival. Main Results: The treatment may be feasible and tolerable in patients with high-risk neuroblastoma, however, the benefits of this regimen for survival outcomes are seen only in patients who were in complete response or very good partial response after induction chemotherapy, before the beginning of treatment with 131I-mIBG. Conclusions: There are uncertainties regarding the effectiveness of treatment with 131I-mIBG for increasing the survival of patients diagnosed with neuroblastoma.
References
Alexandre Spironello, R., Souza Silva-Comar, F. M., Esteves Cardia, G. F., Janeiro, V., Bocchi Pedroso, R., & Nakamura Cuman, R. K. (2020). Mortalidade infantil por câncer no Brasil. Saúde e Pesquisa, 13(1);115-122.
Bleeker, G., Schoot, R. A., Caron, H. N., de Kraker, J., Hoefnagel, C. A., van Eck, B. L., & Tytgat, G. A. (2013). Toxicity of upfront 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis. European journal of nuclear medicine and molecular imaging, 40, 1711-1717.
Castel, V., Canete, A., Melero, C., Acha, T., Navajas, A., García‐Miguel, P., ... & Cruz, O. (2000). Results of the cooperative protocol (N‐III‐95) for metastatic relapses and refractory neuroblastoma. Medical and Pediatric Oncology: The Official Journal of SIOP—International Society of Pediatric Oncology (Societé Internationale d'Oncologie Pédiatrique, 35(6), 724-726.
Claudiani, F., Garaventa, A., Bertolazzi, L., Villavecchia, G. P., Cabria, M., Scopinaro, G., ... & Scielzo, G. (1991). [131I] metaiodobenzylguanidine therapy in advanced neuroblastoma. Journal of nuclear biology and medicine (Turin, Italy: 1991), 35(4), 224-227. https://www.embase.com/search/results?subaction=viewrecord&id=L22269301&from=export
de Camargo, B., de Oliveira Ferreira, J. M., de Souza Reis, R., Ferman, S., de Oliveira Santos, M., & Pombo-de-Oliveira, M. S. (2011). Socioeconomic status and the incidence of non-central nervous system childhood embryonic tumours in Brazil. BMC cancer, 11, 1-6. https://pubmed.ncbi.nlm.nih.gov/21545722
Feng, J., Cheng, F. W., Leung, A. W., Lee, V., Yeung, E. W., Lam, H. C., ... & Li, C. K. (2020). Upfront consolidation treatment with 131I-mIbG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high-risk neuroblastoma. Pediatric Investigation, 4(03), 168-177.https://www.embase.com/search/results?subaction=viewrecord&id=L2006798855&from=export
Garaventa, A., Bellagamba, O., Piccolo, M. S., Milanaccio, C., Lanino, E., Bertolazzi, L., ... & De Bernardi, B. (1999). 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. British journal of cancer, 81(8), 1378-1384.
Hamidieh, A. A., Beiki, D., Paragomi, P., Fallahi, B., Behfar, M., Fard‐Esfahani, A., ... & Ghavamzadeh, A. (2014). The potential role of pretransplant MIBG diagnostic scintigraphy in targeted administration of 131I‐MIBG accompanied by ASCT for high‐risk and relapsed neuroblastoma: A pilot study. Pediatric Transplantation, 18(5), 510-517. https://www.embase.com/search/results?subaction=viewrecord&id=L373480980&from=export
Howard, J. P., Maris, J. M., Kersun, L. S., Huberty, J. P., Cheng, S. C., Hawkins, R. A., & Matthay, K. K. (2005). Tumor response and toxicity with multiple infusions of high dose 131I‐MIBG for refractory neuroblastoma. Pediatric blood & cancer, 44(3), 232-239. https://www.embase.com/search/results?subaction=viewrecord&id=L40209432&from=export
Kayano, D., Wakabayashi, H., Nakajima, K., Kuroda, R., Watanabe, S., Inaki, A., ... & Kinuya, S. (2020). High-dose 131 I-metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan. Annals of nuclear medicine, 34, 397-406. https://www.embase.com/search/results?subaction=viewrecord&id=L2004496894&from=export
Klingebiel, T., Feine, U., Treuner, J., Reuland, P., Handgretinger, R., & Niethammer, D. (1991). Treatment of neuroblastoma with [131I] metaiodobenzylguanidine: long-term results in 25 patients. Journal of Nuclear Biology and Medicine (Turin, Italy: 1991), 35(4), 216-219. https://www.embase.com/search/results?subaction=viewrecord&id=L22269299&from=export
Kraal, K. C., Tytgat, G. A., van Eck‐Smit, B. L., Kam, B., Caron, H. N., & van Noesel, M. (2015). Upfront treatment of high‐risk neuroblastoma with a combination of 131I‐MIBG and topotecan. Pediatric blood & cancer, 62(11), 1886-1891.
Kraal, K. C., van Dalen, E. C., Tytgat, G. A., & Van Eck‐Smit, B. L. (2017). Iodine‐131‐meta‐iodobenzylguanidine therapy for patients with newly diagnosed high‐risk neuroblastoma. Cochrane Database of Systematic Reviews, (4). http://dx.doi.org/10.1002/14651858.CD010349.pub2
Kraker, J., Hoefnagel, K. A., Verschuur, A. C., van Eck, B., van Santen, H. M., & Caron, H. N. (2008). Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. European Journal of Cancer, 44(4), 551-556. https://www.embase.com/search/results?subaction=viewrecord&id=L50061829&from=export
Ladenstein, R. (2011). 102 INVITED Recent Advancements for High Risk Neuroblastoma (HRN) in Europe Through the SIOP Europe Neuroblastoma Group (SIOPEN). European Journal of Cancer, (47), S26. https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01021218/full
Lee, J. W., Lee, S., Cho, H. W., Ma, Y., Yoo, K. H., Sung, K. W., ... & Lim, D. H. (2017). Incorporation of high-dose 131 I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study. Journal of Hematology & Oncology, 10, 1-11.
Lucena, J. N., Alves, M. T. S., Abib, S. C. V., Souza, G. O. D., Neves, R. P. D. C., & Caran, E. M. M. (2018). Aspectos clínicos, epidemiológicos e sobrevida de crianças com neuroblastoma: 21 anos de experiência do instituto de oncologia pediátrica, São Paulo. Revista Paulista de Pediatria, 36, 254-260. http://www.scielo.br/scielo.php?script=sci_arttext&pid=s0103-05822018000300254&lng=pt&tlng=pt
Matthay, K. K., Quach, A., Huberty, J., Franc, B. L., Hawkins, R. A., Jackson, H., ... & Maris, J. M. (2009). Iodine-131—metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. Journal of Clinical Oncology, 27(7), 1020.
Matthay, K. K., Tan, J. C., Villablanca, J. G., Yanik, G. A., Veatch, J., Franc, B., ... & Maris, J. M. (2006). Phase I Dose Escalation of Iodine-131–Metaiodobenzylguanidine With Myeloablative Chemotherapy and Autologous Stem-Cell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study. Journal of Clinical Oncology, 24(3), 500-506.
Matthay, K. K., Weiss, B., Villablanca, J. G., Maris, J. M., Yanik, G. A., DuBois, S. G., ... & Babich, J. (2012). Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. Journal of Nuclear Medicine, 53(7), 1155-1163.https://www.embase.com/search/results?subaction=viewrecord&id=L365165473&from=export
Matthay, K. K., Yanik, G., Messina, J., Quach, A., Huberty, J., Cheng, S. C., ... & Maris, J. M. (2007). Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. Journal of clinical oncology, 25(9), 1054-1060.
Miano, M., Garaventa, A., Pizzitola, M. R., Piccolo, M., Dallorso, S., Villavecchia, G. P., ... & De Bernardi, B. (2001). Megatherapy combining I131 metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone marrow transplantation, 27(6), 571-574.
Mourad Ouzzani, Hossam Hammady, Zbys Fedorowicz, &Ahmed Elmagarmid. (2016). Rayyan — a web and mobile app for systematic reviews. Systematic Reviews (2016) 5:210, 10.1186/s13643-016-0384-4.
Schoot, R. A., Bleeker, G., Caron, H. N., van Eck, B. L., Heij, H. A., de Kraker, J., & Tytgat, G. A. (2013). The role of 131 I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 40, 1516-1522. https://www.embase.com/search/results?subaction=viewrecord&id=L52618838&from=export
Sterne J A, Hernán M A, Reeves B C, Savović J, Berkman N D, Viswanathan M, et al. (2016). ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interven tions. BMJ [Internet]. 355:i4919. https://www.bmj.com/lookup/doi/10.1136/bmj.i4919
Suh, J. K., Koh, K. N., Min, S. Y., Kim, Y. S., Kim, H., Im, H. J., ... & Seo, J. J. (2020). Feasibility and effectiveness of treatment strategy of tandem high‐dose chemotherapy and autologous stem cell transplantation in combination with 131I‐MIBG therapy for high‐risk neuroblastoma. Pediatric Transplantation, 24(2), e13658. https://www.embase.com/search/results?subaction=viewrecord&id=L2004155152&from=export
Wakabayashi, H., Kayano, D., Inaki, A., Araki, R., Kuroda, R., Ikawa, Y. & Kinuya, S. (2020). High-dose 131 I-mIBG as consolidation therapy in pediatric patients with relapsed neuroblastoma and ganglioneuroblastoma: the Japanese experience. Annals of Nuclear Medicine, 34, 840-846. https://www.embase.com/search/results?subaction=viewrecord&id=L2006010535&from=export
Yalcin, B., Kremer, L. C., Caron, H. N., & van Dalen, E. C. (2013). High‐dose chemotherapy and autologous haematopoietic stem cell rescue for children with high‐risk neuroblastoma. Cochrane Database of Systematic Reviews, (8). http://dx.doi.org/10.1002/14651858.CD006301.pub4
Yanik, G. A., Parisi, M. T., Shulkin, B. L., Naranjo, A., Kreissman, S. G., London, W. B., & Matthay, K. K. (2013). Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s oncology group. Journal of nuclear medicine, 54(4), 541-548. https://www.embase.com/search/results?subaction=viewrecord&id=L368653971&from=export
Zhou, M. J., Doral, M. Y., DuBois, S. G., Villablanca, J. G., Yanik, G. A., & Matthay, K. K. (2015). Different outcomes for relapsed versus refractory neuroblastoma after therapy with 131I-metaiodobenzylguanidine (131I-MIBG). European Journal of Cancer, 51(16), 2465-2472. https://www.embase.com/search/results?subaction=viewrecord&id=L605511968&from=export
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Roberto Carlos Lyra da Silva; Carlos Roberto Lyra da Silva; Ayla Maria Farias de Mesquita; Ana Paula Siqueira; Jessica Silva Brunoni; Lilian Reinaldi Ribeiro; Regina Bokehi Nigri
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
